| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
HIF-1α-IN-8 (Compound N41) (20 μM, 48 h) inhibited the secretion of inflammatory factors IL-6 and NO in C8-D1A cells[1]. HIF-1α-IN-8 (5-50 μM, 12 h) reduced hypoxia-induced ROS production and apoptosis in C8-D1A cells[1]. HIF-1α-IN-8 (5-20 μM, 24 h) inhibited the expression of key proteins (HIF-1α, IKKα, p65, IκBα) in the HIF-1α/IKKα/NF-κB signaling pathway and reduced the expression of blood-brain barrier permeability-related proteins MMP-9 and AQP-4 in C8-D1A cells[1].
|
|---|---|
| ln Vivo |
HIF-1α-IN-8 (Compound N41) (25-100 mg/kg, administered by gavage, once daily for 3 days) reduced brain water content and oxidation levels in a high- and low-pressure cerebral edema (HACE) model [1].
|
| Cell Assay |
Apoptosis Analysis[1]
Cell Types: C8-D1A cells Tested Concentrations: 5, 10, 20, 50 μM Incubation Duration: 12 h Experimental Results: Reduced apoptosis in C8-D1A cells. Western Blot Analysis[1] Cell Types: C8-D1A cells Tested Concentrations: 5, 10, 20 μM Incubation Duration: 24 h Experimental Results: Inhibited the expression of key proteins (HIF-1α, IKKα, p65, IκBα) in the HIF-1α/IKKα/NF-κB signaling pathway. Reduced the expression of blood-brain barrier permeability-related proteins MMP-9 and AQP-4 in C8-D1A cells. |
| Animal Protocol |
Animal/Disease Models: Adult male C57BL/6 mice were intraperitoneally injected with 0.5 mg/kg LPS and after 30 min of adaptation, mice were placed in a ProOx-810 Animal Low-Pressure Oxygen Control System to simulate a 7000 m high-altitude environment for 12 h to establish the HACE model[1]
Doses: 25 mg/kg, 50 mg/kg, 100 mg/kg Route of Administration: i.g. once daily, 3 days Experimental Results: Reduced weight loss in a dose-dependent manner. Decreased brain water content (BWC) dose-dependently. Regulated oxidative stress in brain tissue. Suppressed inflammatory factor (IL-6, TNF-α)levels. Alleviated brain tissue pathological damage. Inhibited protein expression in the HIF-1α/IKKα/NF-κB signaling pathway. |
| References |
| Molecular Formula |
C29H30FNO7
|
|---|---|
| Molecular Weight |
523.55
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9100 mL | 9.5502 mL | 19.1004 mL | |
| 5 mM | 0.3820 mL | 1.9100 mL | 3.8201 mL | |
| 10 mM | 0.1910 mL | 0.9550 mL | 1.9100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
